COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?

Şen, Selçuk; Üresin, Ali Yağız

Journal Metrics

Impact Factor (2022): 0.8
CiteScore (2022): 1.2
Source Normalized Impact
per Paper: 0.22
SCImago Journal Rank: 0.348

52/3Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and

In titles and abstracts

In keywords

In all

Archives of the Turkish Society of Cardiology

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option? [Turk Kardiyol Dern Ars]

Turk Kardiyol Dern Ars. 2020; 48(7): 631-634 | DOI: 10.5543/tkda.2020.64072

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?

Selçuk Şen, Ali Yağız Üresin
Department of Medical Pharmacology, Division of Clinical Pharmacology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Keywords: COVID-19, ACE inhibitor, angiotensin receptor blocker, direct renin inhibitor, aliskiren

How to cite this article
Selçuk Şen, Ali Yağız Üresin. COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?. Turk Kardiyol Dern Ars. 2020; 48(7): 631-634

Corresponding Author: Selçuk Şen, Türkiye
Manuscript Language: English

TOOLS English Full Text Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author Similar articles PubMed Google Scholar